Novavax links vaccine to full protection against severe COVID-19 caused by emerging variants AstraZeneca again cuts coronavirus vaccine delivery targets in Europe One year of COVID: As scientific innovation went into overdrive, here's what happened at UnitedHealth Group GSK, Novo and Roche meds hit pandemic potholes while Dupixent, Humira stood strong: analysts Sanofi, hit by COVID vaccine setback, kickstarts mRNA trial with Translate Bio Biden signs $1.9T COVID-19 package that boosts ACA subsidies, rural hospital funding Tele-testing tech provider ixlayer raises $75M to scale up health screenings Pfizer, riding high on COVID-19 vaccine launch, pays CEO Bourla $21 million for 2020 Biopharma roundup—U.S. debates what to do with 30M unused AZ vaccines Featured Story | By Nick Paul Taylor Novavax has linked its COVID-19 vaccine to 100% efficacy against severe disease in countries where variants of concern are prevalent. The final phase 3 data suggest NVX-CoV2373 may protect against the worst outcomes caused by the coronavirus variants, even though the mutations limit its efficacy. read more |
| |
|---|
|
Top Stories By Eric Sagonowsky After a very public back-and-forth over COVID-19 vaccine supplies in Europe earlier this year, AstraZeneca said it would aim to deliver 40 million doses in the first quarter. It’s now rolling the estimate back to 30 million, Reuters reports—the same figure that triggered the initial controversy. Meanwhile, in some countries, doses are going unused. read more By Paige Minemyer The research team at UHG has rolled out a slew of projects over the past year in response to the pandemic, ranging from studies on COVID therapies to home health to protective equipment. read more By Eric Sagonowsky As the COVID-19 pandemic reshaped the global economy, some pharma companies coped better than others, and the who and why offer some hints about who's best suited to weather a future crisis. That's the word from Jefferies analysts, who identified some pitfalls—and some boons—for drugmakers on pandemic time. read more By Ben Adams Sanofi doubled down on its original 2018 pact with Translate Bio last year as the pair teamed up for an mRNA approach to COVID vaccines, and today the two announced they are starting clinical trials using the tech. read more By Robert King President Biden on Thursday signed into law a $1.9 trillion COVID-19 relief package that boosts ACA subsidies and gives more money to rural hospitals, sending the legislation to President Joe Biden for his signature. read more By Conor Hale The health-tech company ixlayer has raised $75 million to support its telehealth platform for connecting laboratory diagnostics with the people who need them on a large scale. read more By Eric Sagonowsky Thanks to the success of its COVID-19 vaccine, the drug giant Pfizer has become a household name around the globe—and the company's eyeing $15 billion in sales from the shot this year. For his work steering the ship through 2020, CEO Albert Bourla collected a pay package worth more than $21 million. read more By Kevin Dunleavy,Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Conor Hale AstraZeneca has again lowered its vaccine supply estimate to Europe. After a successful year dealing with COVID-19, Pfizer rewarded CEO Albert Bourla with more than $21 million. Jefferies reviews the response of pharma companies to the pandemic. Novavax vaccine 100% effective protection vs. severe COVID-19 cases. Altimmune, Lonza expand vaccine agreement. read more |
